Penile cancer
diseaseOn this page
Also known as cancer of penismalignant neoplasm of penismalignant neoplasm of the penismalignant penile neoplasmmalignant penile tumormalignant penile tumourmalignant penis neoplasmmalignant tumor of penismalignant tumor of the penismalignant tumour of penismalignant tumour of the penispenile neoplasmpenis cancer
Summary
Penile cancer (MONDO:0001325) is a cancer and 63 clinical trials. Top therapeutic interventions include cabozantinib, avelumab, and cabazitaxel. A subtype of male reproductive organ cancer — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Classification: Cancer
- Prevalence: 1-9 / 100 000 (Europe) [Orphanet-validated]
- Clinical trials: 63
Clinical features
Epidemiology
Prevalence records
5 prevalence record(s), Orphanet:
| Type | Class | Value | Geography | Validation |
|---|---|---|---|---|
| Annual incidence | 1-9 / 100 000 | 1.075 | Europe | Validated |
| Annual incidence | 1-9 / 100 000 | 4.85 | Brazil | Validated |
| Annual incidence | 1-9 / 100 000 | 3.5 | Uganda | Validated |
| Annual incidence | 1-9 / 100 000 | 1.21 | United Kingdom | Validated |
| Annual incidence | 1-9 / 1 000 000 | 0.58 | United States | Validated |
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | penile cancer |
| Mondo ID | MONDO:0001325 |
| Orphanet | 398043 |
| DOID | DOID:11615 |
| ICD-10-CM | C60 |
| ICD-11 | 969101922 |
| NCIT | C7547 |
| SNOMED CT | 363516004 |
| UMLS | C0153601 |
| MedGen | 102277 |
| GARD | 0009366 |
| Anatomy (UBERON) | UBERON:0000989 |
| Is cancer (heuristic) | yes |
Also known as: cancer of penis · malignant neoplasm of penis · malignant neoplasm of the penis · malignant penile neoplasm · malignant penile tumor · malignant penile tumour · malignant penis neoplasm · malignant tumor of penis · malignant tumor of the penis · malignant tumour of penis · malignant tumour of the penis · penile cancer · penile neoplasm · penis cancer
Disease family
This is a subtype of male reproductive organ cancer. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.
Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › cancer › reproductive system cancer › male reproductive organ cancer › penile cancer
Related subtypes (6): epididymis cancer, spermatic cord cancer, carcinoma of Cowper glands, testicular cancer, prostate cancer, scrotum cancer
Subtypes (4): penile sarcoma, glans penis cancer, penile urethral cancer, penile carcinoma
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
No tiered GWAS variants or ClinVar records for this disease.
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
No druggable-target or therapeutic data for this disease’s cohort.
Clinical trials & evidence
Clinical trials
Clinical trials: 63.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| PHASE2 | 29 |
| Not specified | 23 |
| PHASE1 | 7 |
| PHASE1/PHASE2 | 3 |
| PHASE3 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT06465914 | PHASE3 | ACTIVE_NOT_RECRUITING | A Phase III Study to Evaluate the Efficacy, Immunogenicity and Safety of the 9-valent HPV Vaccine in Chinese Males |
| NCT02721732 | PHASE2 | ACTIVE_NOT_RECRUITING | Pembrolizumab in Treating Patients With Rare Tumors That Cannot Be Removed by Surgery or Are Metastatic |
| NCT02817958 | PHASE2 | ACTIVE_NOT_RECRUITING | Evaluation of Lymphadenectomy and Chemotherapy TIP on Inguinal Lymph Nodes in Squamous Cell Carcinoma of the Penis |
| NCT03333616 | PHASE2 | ACTIVE_NOT_RECRUITING | Nivolumab Combined With Ipilimumab for Patients With Advanced Rare Genitourinary Tumors |
| NCT03391479 | PHASE2 | ACTIVE_NOT_RECRUITING | A Study of Avelumab in Penile Cancer Who Are Unfit for or Have Progressed After Platinum-Based Chemotherapy |
| NCT03866382 | PHASE2 | RECRUITING | Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors |
| NCT04708470 | PHASE1/PHASE2 | ACTIVE_NOT_RECRUITING | A Phase I/II Study of Combination Immunotherapy for Advanced Cancers Including HPV-Associated Malignancies, Small Bowel, and Colon Cancers |
| NCT05639972 | PHASE1/PHASE2 | RECRUITING | E7 T-cell Receptor (TCR) -T Cell Induction Therapy for Locoregionally Advanced HPV-associated Cancers |
| NCT05686226 | PHASE2 | RECRUITING | E7 TCR-T Cell Immunotherapy for Human Papillomavirus (HPV) Associated Cancers |
| NCT06104618 | PHASE2 | RECRUITING | Enfortumab Vedotin for the Treatment of Patients With Metastatic or Unresectable Squamous Cell Carcinoma of the Penis |
| NCT06353906 | PHASE2 | RECRUITING | Carboplatin/Paclitaxel + Pembrolizumab for Locoregionally Advanced Penile Cancer |
| NCT06415318 | PHASE2 | RECRUITING | TIP Regimen Combined With Triplizumab Neoadjuvant Therapy for Locally Advanced Penile Cancer |
| NCT06683846 | PHASE2 | RECRUITING | Ivonescimab in the Treatment of Multiple Advanced Tumors |
| NCT06684327 | PHASE2 | RECRUITING | Multi-cohort, Single-arm Phase II Study of Albumin-paclitaxel, Ifosfamide, and Cisplatin in the Treatment of Rare Advanced Tumors |
| NCT07101822 | PHASE2 | NOT_YET_RECRUITING | A PHASE II, RANDOMIZED STUDY TO ASSESS MAINTENANCE THERAPY WITH CEMIPLIMAB VERSUS BEST SUPPORTIVE CARE AFTER 1ST LINE PLATINUM-BASED CHEMOTHERAPY IN ADVANCED/RECURRENT PENILE CANCER |
| NCT07384416 | PHASE2 | RECRUITING | QL1706 Plus Lenvatinib in Previously Treated Penile Cancer |
| NCT07497919 | PHASE2 | NOT_YET_RECRUITING | A Study of Becotatug Vedotin Combined With Pucotenlimab in the Treatment of EGFR-Positive Advanced Penile Cancer |
| NCT07518979 | PHASE2 | NOT_YET_RECRUITING | EGFR-ADC (Becotatug Vedotin) Combined With PD-1 Inhibitor (Pucotenlimab) in Neoadjuvant Treatment of Advanced Penile Cancer |
| NCT00002506 | PHASE2 | COMPLETED | Isotretinoin Plus Interferon in Treating Patients With Recurrent Cancer |
| NCT00058448 | PHASE2 | TERMINATED | S0224, Docetaxel in Treating Patients With Locally Advanced or Metastatic Penile Cancer (TERMINATED) |
| NCT00066391 | PHASE2 | COMPLETED | Irinotecan and Cisplatin in Treating Patients With Locally Advanced or Metastatic Penile Cancer |
| NCT00512096 | PHASE2 | COMPLETED | Neoadjuvant Chemotherapy for Patients With Squamous Cell Carcinoma of the Penis |
| NCT01209325 | PHASE2 | COMPLETED | Vaccine Therapy in Preventing Human Papillomavirus Infection in Young HIV-Positive Male Patients Who Have Sex With Males |
| NCT01585428 | PHASE2 | COMPLETED | Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Human Papillomavirus-Associated Cancers |
| NCT02280811 | PHASE1/PHASE2 | COMPLETED | T Cell Receptor Immunotherapy Targeting HPV-16 E6 for HPV-Associated Cancers |
| NCT03114254 | PHASE2 | COMPLETED | A Trial of Cabazitaxel Chemotherapy in Relapsed Locally Advanced &/or Metastatic Carcinoma of the Penis |
| NCT03427411 | PHASE2 | COMPLETED | M7824 in Subjects With HPV Associated Malignancies |
| NCT03439085 | PHASE2 | TERMINATED | DNA Plasmid-encoding Interleukin-12/HPV DNA Plasmids Therapeutic Vaccine INO-3112 and Durvalumab in Treating Patients With Recurrent or Metastatic Human Papillomavirus Associated Cancers |
| NCT03686332 | PHASE2 | COMPLETED | PEnile Cancer Radio- and Immunotherapy CLinical Exploration Study |
| NCT03774901 | PHASE2 | UNKNOWN | Maintenance Avelumab Immunotherapy in Patients With Locally Advanced or Metastatic Squamous Cell Penile Carcinoma |
| NCT04231981 | PHASE2 | COMPLETED | Efficacy of INCMGA00012 in Penile Squamous Cell Carcinoma (ORPHEUS) |
| NCT04357873 | PHASE2 | COMPLETED | Efficacy of Immunotherapy Plus a Drug in Patients With Progressive Advanced Mucosal Cancer of Different Locations |
| NCT04475016 | PHASE2 | COMPLETED | TIP (Paclitaxel + Ifosfamide + Cisplatin) Combined With Nimotuzumab & Triprilimab as Neoadjuvant Treatment in Locally Advanced Penile Cancer |
| NCT02496208 | PHASE1 | ACTIVE_NOT_RECRUITING | Cabozantinib S-malate and Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Genitourinary Tumors |
| NCT04491942 | PHASE1 | ACTIVE_NOT_RECRUITING | Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or Cisplatin and Gemcitabine) for Advanced Solid Tumors With Emphasis on Urothelial Cancer |
| NCT06544720 | PHASE1 | RECRUITING | SCG142 TCR-T Cells for Human Papillomavirus-Associated Carcinomas |
| NCT07054307 | PHASE1 | RECRUITING | MRG003 Plus HX008 as First-Line Treatment for EGFR-Positive Locally Advanced or Metastatic Penile Squamous Cell Carcinoma |
| NCT00019110 | PHASE1 | COMPLETED | Vaccine Therapy in Treating Patients With Advanced or Recurrent Cancer |
| NCT05376202 | PHASE1 | COMPLETED | Image Guided Penile Cancer Surgery |
| NCT05518201 | PHASE1 | COMPLETED | Evaluate the Safety and Immunogenicity of a 9-valent HPV Vaccine in Chinese Healthy Male Aged 9-45 Year-old |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| CABOZANTINIB | 4 | 4 |
| AVELUMAB | 4 | 1 |
| CABAZITAXEL | 4 | 1 |
| ENFORTUMAB VEDOTIN | 4 | 1 |
| ISOTRETINOIN | 4 | 1 |
| RETIFANLIMAB | 4 | 1 |
| BECOTATUG VEDOTIN | 3 | 2 |
| BINTRAFUSP ALFA | 3 | 2 |
| PUCOTENLIMAB | 3 | 2 |
| ENTINOSTAT | 3 | 1 |
| NIMOTUZUMAB | 3 | 1 |
| ELIMUSERTIB | 1 | 1 |